Salute e Benessere

Cambrex Completes Expansion of Snapdragon Chemistry Facility in Waltham…

This expansion adds an additional 12,000 square feet to Snapdragon's active pharmaceutical ingredient (API) development and manufacturing facility, including new process research and development suites with 24 hoods, a GMP stability suite, and a fifth GMP kilo-lab, designed for multi-step, end-to-end continuous processing. The new labs feature 100L and 60L glass-lined steel reactors, a 10L plug flow reactor, tangential flow filtration and nanofiltration skid, 5kW photoreactor and a...
PR Newswire
16/05/2023

Evaxion to host R&D Day on May 25, 2023

/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, today announced that it will hold an R&D Day at 12:30 p.m CEST on May 25, 2023. The R&D Day will feature a series of talks from Evaxion scientists and collaborators, sharing previously unreleased preclinical data highlighting the use of Evaxion's proprietary genetic immune adjuvant (Antigen Presenting Cell targeting)...
Nasdaq GlobeNewswire
16/05/2023

Major Shareholder Announcement - AIM international Mutual Funds

ANNOUNCEMENT NO. 23816 May 2023Major shareholder announcementMajor shareholder announcement–AIM International Mutual Funds Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that Invesco Ltd. has informed ChemoMetec A/S that AIM International Mutual Funds (Invesco International Mutual Funds) holds 881,141 shares in ChemoMetec A/S corresponding to 5.06% of the share capital, and that the shareholding thus exceeds the 5 per cent limit in...
Nasdaq GlobeNewswire
16/05/2023

Beactica Therapeutics to present breakthrough in YAP-TEAD programme at the Hippo…

The presentation will showcase a breakthrough in the development of novel cell-active targeted degraders of TEAD, with therapeutic potential against multiple types of life-threatening cancers. The degraders developed are based on previously generated proprietary inhibitors of the YAP–TEAD protein–protein interaction. These have now been developed into bifunctional compounds with the additional ability to induce selective degradation of TEAD through the proteasome, the cell's own waste disposal…
PR Newswire
16/05/2023

Medit continues to see strong scanner adoption in Q1 2023

According to GB Ko, CEO of Medit, " At Medit, we take pride in our easy-to-use and accurate scanners, which continue to assist dentists on their journey towards digital practices. Our scanners are equipped with Medit Apps, which help to make digital dentistry more streamlined and accessible for both learning and practice." According to GB Ko, CEO of Medit, " At Medit, we take pride in our easy-to-use and accurate scanners, which continue to assist dentists on their journey towards…
PR Newswire
16/05/2023

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance…

With a global manufacturing network that includes facilities in the United States, Ireland, Germany, China and Singapore, WuXi Biologics leverages its development and manufacturing technologies to provide more efficient and cost-effective production of drug substances (DS) and drug products (DP), delivering commercial biologics for global clients and enabling promising treatments delivered to patients worldwide. With a global manufacturing network that includes facilities inthe United States...
PR Newswire
16/05/2023

Tetra Pharm Technologies strengthens management board

"Tetra Pharm Technologies has reached a size that makes it necessary to expand the management board. We are very ambitious about our future growth potential, and the expansion of the management team with experienced profiles such as Steen and Jacob, is an obvious and timely strengthening of the company," says Martin Rose, CEO, Tetra Pharm Technologies. " Tetra Pharm Technologies has reached a size that makes it necessary to expand the management board. We are very ambitious about…
PR Newswire
16/05/2023

Former U.S. White House Surgeon and FDA Medical Officer joins Bioretec team

Dr. Dublon is a board-certified podiatric surgeon specializing in diagnosing and treating conditions in the foot and ankle of people of all ages. In addition, he has specialized training and education in podiatric medicine, surgery, and orthopedics. Earlier, Dr. Dublon served at the U.S. Food and Drug Administration (FDA) on the review team as a Medical Officer in the Division of Restorative, Repair, and Trauma evaluating orthopedic products. Furthermore, he has served as a Deputy Service Chief…
PR Newswire
16/05/2023

iMDsoft, a global leader in clinical information systems, partners with…

This partnership with RCA, marks an important milestone for iMDsoft, as it is the company's first foray into the African continent reflecting the growing readiness of the region to adopt dedicated, advanced IT solutions in the critical care and perioperative space. This partnership with RCA, marks an important milestone for iMDsoft, as it is the company's first foray into the African continent reflecting the growing readiness of the region to adopt dedicated, advanced IT solutions in the...
PR Newswire
16/05/2023

Nexstim Plc resolved on new stock option plans 2023A-C and 2023H

Company Announcement , Helsinki, 16May 2023 at 9:30 AM (EEST) Nexstim Plc resolved on new stock option plans 2023A-C and 2023H Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that the Board of Directors of Nexstim resolved on May 15, 2023, to launch a new stock option plan 2023A-C aimed at the personnel, management and other interest groups of Nexstim Plc and its subsidiaries, by virtue of an authorization granted by Annual General Meeting of...
Nasdaq GlobeNewswire
16/05/2023

Aino Health interim report January-march 2023

Strong license growth, Increased net sales, Improved results, Improved operative cash flow January–March 2023• Net sales were KSEK 6,180 (5,424)• Profit/loss after financial items was KSEK -2,791 (-3,722)• Earnings per share were SEK -0.1 (-0.1)We are proud to present our continued success and the latest news from Q1 2023. Happily, we can announce that our focus on increased license growth has had results. Compared with the same period last year, we have experienced an...
Nasdaq GlobeNewswire
16/05/2023

Implantica announces that RefluxStop™ results were presented at the DDW…

Despite the IEM condition in this group of 20 patients, all patients are showing complete resolution or significant improvement of reflux symptoms. Despite the IEM condition in this group of 20 patients, all patients are showing complete resolution or significant improvement of reflux symptoms. "These initial positive outcomes seen in patients with poor esophageal motility using RefluxStop™ may position the procedure as a truly viable surgical solution for this patient population which...
PR Newswire
16/05/2023

Askel Healthcare to raise 5 million euros for clinical research of its COPLA® -…

Key highlights of the share issue: Key highlights of the share issue: - The company is offering 7.56-21.42% of equity forEUR 8.10per share with a minimum investment of 50 shares. Shares are offered globally through brokers Invesdor GmbH and Oneplanetcrowd B.V. Additional details are available on the campaign website athttps://www.invesdor.com/rounds/f589c08e-3245-4ad9-ba03-96c3277b0c43#/. - The subscription period is 16 May- 18 June 2023. - Askel Healthcare's mission is to...
PR Newswire
16/05/2023

Philips provides update on completed set of test results for CPAP/BiPAP sleep…

Amsterdam, the Netherlands –RoyalPhilips (NYSE: PHG; AEX: PHIA), today provides an update on the comprehensive test and research program of its subsidiary Philips Respironics to assess potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam in specific sleep therapy and ventilator devices under the voluntary June 2021 recall notification/field safety notice .* The risk assessments have now been completed for the CPAP/BiPAP sleep therapy...
Nasdaq GlobeNewswire
16/05/2023

ONWARD Reports Q1 Business Update and Year-To-Date Highlights

First-in-Human Use of the ARC-IM™ LeadNew Breakthrough Device Designation Awarded by the U.S. FDA for ARC Therapy™, Bringing Total to 9 10 Additional Patents Issued, Bringing Total Pending and Issued Patents to More than 340 and Strengthening First-Mover Advantage EINDHOVEN, the Netherlands, May16, 2023(GLOBE NEWSWIRE) --ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in...
Nasdaq GlobeNewswire
16/05/2023

Calliditas Therapeutics: Interim Report Q1, 2023

"In March we announced that the global NefIgArd Phase 3 trial successfully met its primary endpoint, estimated glomerular filtration rate (eGFR), with a p value < 0.0001. Achieving this clinically relevant endpoint of kidney filtration capability represents a crowning achievement after well over a decade of pioneering work in IgA nephropathy. Nefecon, commercially available in the US and Europe under the brand name TARPEYO® and Kinpeygo® respectively, seems to be disease modifying…
PR Newswire
16/05/2023

Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights…

Vivoryon Therapeutics N.V.Reports Q1 2023 Financial Results and Highlights Operational Progress Halle (Saale) / Munich, Germany, May16 , 2023– Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced financial results and corporate updates for the first quarter of...
Nasdaq GlobeNewswire
16/05/2023

GEMO Collaborate with Switzerland Artist ELLA TJADER to Empower Women to be…

ELLA TJADER is a renowned illustrator from Switzerland who draws inspiration from the richness of nature in her exquisite, delicate, and elegant works. She specializes in fine and natural lines and rich colors, and her works are like a beautiful song of nature. GEMO was inspired by the Alps and the nature of Thunersee and Lake Brienz in Switzerland and the magnificent Switzerland mountains. Took the Alpine traditional spa physiotherapy as an anti-aging idea to study the mechanism of skin aging…
PR Newswire
16/05/2023

Health Canada accepts New Drug Submission for lecanemab as treatment for early…

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region and currently Eisai and BioArctic are preparing for a joint commercialization in the region. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen...
PR Newswire
16/05/2023

Clarification regarding announcement of senior management changes in SciBase

"We thank Simon for his efforts as Managing Director at SciBase. During his nine years as CEO, SciBase has transitioned from being a research-oriented company to a commercial stage company with products approved and marketed in the US, Europe and Australia. Obtaining the PMA for Nevisense in the US in 2017 and being able to subsequently secure Medicare reimbursement earlier this year, was the culmination of Simon's efforts to bring the company's technologies to the market and to the benefit…
PR Newswire
16/05/2023

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early…

TOKYO and CAMBRIDGE, Mass., May15, 2023(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of early Alzheimer's…
Nasdaq GlobeNewswire
16/05/2023

ERYTECH Provides Update on the Announced Combination with PHERECYDES

ERYTECH Provides Update on the Announced Combination with PHERECYDES Entry into a definitive merger agreement between ERYTECH and PHERECYDESCompletion of a contribution in kind of PHERECYDES shares to ERYTECHCombination with PHERECYDES to be submitted to shareholders' vote on June 23, 2023 Lyon (France) and Cambridge (MA, US) ,May 15 , 2023– ERYTECH Pharma (Nasdaq & Euronext: ERYP),aclinical-stage biopharmaceutical...
Nasdaq GlobeNewswire
15/05/2023

MDxHealth Reports Q1-2023 Results

NEWS RELEASE - REGULATED INFORMATION 15MAY 2023 , 4:00PM EDT / 22:00 CET MDxHealth Reports Q1-2023Results Year-over-year revenues increase by 141% to $14.7 million; excluding GPS, revenues up 39% Gross margin expanded by 1,270 basis points over prior year periodPositive Local Coverage Determination (LCD), extending coverage for Select mdx test to MedicarepopulationIRVINE, CA, and HERSTAL, BELGIUM...
Nasdaq GlobeNewswire
15/05/2023

Oxurion Announces Results of the Annual Shareholders' Meeting of 2 May 2023

Regulated Information Leuven, Belgium, Boston, MA, US – May 15 , 2023–08 .00 PM CET– Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, held its annual shareholders' meeting on May 2, 2023. The shareholders approved all items on the agenda of the annual shareholders' meeting. All documents pertaining to the annual shareholders'...
Nasdaq GlobeNewswire
15/05/2023
Altri  Comunicati